FDA
# EUA Revocations
`Revocation 'Pre-Omicron`
- Bamlanivimab monotherapy (w/o concomitant etesevimab)

`Revocation in Nationwide Omicron Domianance`
- Bamlanivimab
- Etesevimab 
- Casirivimab
- Imdevimab

# EUA Active
Treatment, High Risk of Progression post-seroconversion:
- Sotrovimab

PrEP, certain Immunocompromised High Risk population:
- Tixagavimab
- Cilgavimab
